Drug Trial Radar · NCT00385697
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
554
Actual
Start
Oct 2006
Primary completion
Jun 2010
Study completion Aug 2011
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Oct 11, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this protocol is to assess the efficacy, tolerability, and safety of MGA031 when administered according to 3 different MGA031 dosing regimens in children and adults with recent-onset (diagnosis within past 12 weeks) type 1 diabetes mellitus. All regimens will be administered as an addition to insulin and other standard of care treatments. Efficacy will be defined primarily by the capacity of MGA031 to markedly reduce typical insulin requirements while maintaining relatively normal blood sugar levels. Other studies involving the study drug use the name hOKT3γ1 (Ala-Ala). MGA031, a humanized monoclonal antibody, is the name used for hOKT3γ1 (Ala-Ala) that is produced by MacroGenics, Inc. The United States Adopted Name (USAN) for MGA031 is teplizumab.
Conditions
- Type 1 Diabetes Mellitus
Interventions
TeplizumabBiological
Daily IV dosing for 14 days, repeated at Week 26
PlaceboDrug
Daily IV dosing for 14 days, repeated at Week 26
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Time frame: 52 weeks after randomization
- Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Time frame: 52 weeks after first dose
- Mean HbA1c Change From Baseline in Segment 2Time frame: 52 weeks after randomization
- Mean HbA1c Change From Baseline in Segment 1Time frame: 52 weeks after first dose
Locations
115 sites in 16 countries. Site status is shown where the registry gives one.
UAB School of Medicine
Birmingham, Alabama
NEA Clinic
Jonesboro, Arkansas
Arkansas Children's Hospital
Little Rock, Arkansas
Diabetes Medical Center of California
Northridge, California
UCSF Medical Center
San Francisco, California
University of Colorado Health Sciences Center
Aurora, Colorado
Yale University
New Haven, Connecticut
Christiana Care Research Institute
Newark, Delaware
Richard Hays, MD
Wellington, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
Humphrey Diabetes Center
Boise, Idaho
Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho
Riley Hospital for Children
Indianapolis, Indiana
University of Iowa Children's Hospital
Iowa City, Iowa
Mid-America Diabetes Associates, PA
Wichita, Kansas
Commonwealth Biomedical Research, LLC
Madisonville, Kentucky
St. Agnes Hospital
Baltimore, Maryland
Maryland Diabetes & Endocrine Associates
Rockville, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Baystate Medical Center
Springfield, Massachusetts
Alzohaili Medical Consultants
Dearborn, Michigan
The Children's Mercy Hospital
Kansas City, Missouri
Creighton Diabetes Center
Omaha, Nebraska
Saint Barnabas Medical Center
Livingston, New Jersey
University of Medicine & Dentistry of NJ
New Brunswick, New Jersey
Albany Medical Center
Albany, New York
Schneider Children's Hospital
New Hyde Park, New York
Joslin Diabetes Center
Syracuse, New York
Cleveland Clinic
Cleveland, Ohio
St. Mary Medical Center
Langhorne, Pennsylvania
Sumter Medical Specialists
Sumter, South Carolina
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee
Methodist Healthcare
Memphis, Tennessee
Research Institute of Dallas
Dallas, Texas
Spectra Research Center
McAllen, Texas
Diabetes and Glandular Disease Research
San Antonio, Texas
Endocrine Research Specialists
Ogden, Utah
Pacific Northwest Research Institute
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Alberta Children's Hospital
Calgary, Alberta, Canada
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.